Comparative safety and efficacy against Bacillus anthracis of protective antigen and live vaccines in mice.
about
Contribution of individual toxin components to virulence of Bacillus anthracisPrinciples of antidote pharmacology: an update on prophylaxis, post-exposure treatment recommendations and research initiatives for biological agentsAnthrax vaccination strategiesImmunization of mice with formalin-inactivated spores from avirulent Bacillus cereus strains provides significant protection from challenge with Bacillus anthracis AmesMonoclonal antibody therapies against anthraxA high-affinity monoclonal antibody to anthrax protective antigen passively protects rabbits before and after aerosolized Bacillus anthracis spore challengeAttenuated nontoxinogenic and nonencapsulated recombinant Bacillus anthracis spore vaccines protect against anthrax.Genome-based bioinformatic selection of chromosomal Bacillus anthracis putative vaccine candidates coupled with proteomic identification of surface-associated antigens.Mucosal or parenteral administration of microsphere-associated Bacillus anthracis protective antigen protects against anthrax infection in mice.Identification of a second collagen-like glycoprotein produced by Bacillus anthracis and demonstration of associated spore-specific sugars.Proteomic profiling and identification of immunodominant spore antigens of Bacillus anthracis, Bacillus cereus, and Bacillus thuringiensis.Efficacy of a vaccine based on protective antigen and killed spores against experimental inhalational anthraxAnthrax prevention and treatment: utility of therapy combining antibiotic plus vaccine.CpG oligodeoxynucleotides adsorbed onto polylactide-co-glycolide microparticles improve the immunogenicity and protective activity of the licensed anthrax vaccineVaccination against anthrax with attenuated recombinant strains of Bacillus anthracis that produce protective antigenAnthrax spores make an essential contribution to vaccine efficacyDirect inhibition of T-lymphocyte activation by anthrax toxins in vivo.DNA vaccines for biodefense.Identification of the immunogenic spore and vegetative proteins of Bacillus anthracis vaccine strain A16R.Topical application of Escherichia coli-vectored vaccine as a simple method for eliciting protective immunityVenezuelan equine encephalitis virus-vectored vaccines protect mice against anthrax spore challenge.Protective immunity induced by Bacillus anthracis toxin-deficient strains.Passive protection by polyclonal antibodies against Bacillus anthracis infection in guinea pigs.Murine aerosol challenge model of anthraxExpression of either lethal toxin or edema toxin by Bacillus anthracis is sufficient for virulence in a rabbit model of inhalational anthraxSystemic but not mucosal immunity induced by AVA prevents inhalational anthraxThe Exosporium Layer of Bacterial Spores: a Connection to the Environment and the Infected HostRecombinant exosporium protein BclA of Bacillus anthracis is effective as a booster for mice primed with suboptimal amounts of protective antigen.Next-Generation Bacillus anthracis Live Attenuated Spore Vaccine Based on the htrA(-) (High Temperature Requirement A) Sterne Strain.Characterization of a multi-component anthrax vaccine designed to target the initial stages of infection as well as toxaemia.CpG oligonucleotides accelerate and boost the immune response elicited by AVA, the licensed anthrax vaccine.CpG oligonucleotides improve the protective immune response induced by the licensed anthrax vaccine.Effect of CpG oligonucleotides on vaccine-induced B cell memory.Immunization against anthrax with Bacillus anthracis protective antigen combined with adjuvants.Protection against anthrax with recombinant virus-expressed protective antigen in experimental animalsImmunization against anthrax with aromatic compound-dependent (Aro-) mutants of Bacillus anthracis and with recombinant strains of Bacillus subtilis that produce anthrax protective antigen.Recombinant Bacillus anthracis spore proteins enhance protection of mice primed with suboptimal amounts of protective antigen.Biochemical and physiological changes induced by anthrax lethal toxin in J774 macrophage-like cells.Anthrax, toxins and vaccines: a 125-year journey targeting Bacillus anthracis.Progress toward the Development of a NEAT Protein Vaccine for Anthrax Disease.
P2860
Q24652917-CF7A7B38-9A53-4210-80A2-AEDFC96FB1E6Q28384852-43B624FA-3970-42D6-B1DE-282C68B9A364Q28392248-89776C26-CA3D-48CD-9190-1D2F6A5A3375Q28392659-E40E4DFB-F923-41E0-9AC0-C2DF064A0810Q28393072-85CC365A-FA4E-4739-B173-63DD9D1B5ADFQ28398021-23C28611-F7E3-40D4-90EC-F8564DF279C1Q30651835-3E21F0EB-B960-4E0D-9702-F5DC1372C178Q30783500-F3F18750-4DC5-4B9F-BA7F-09C09CF87EAEQ32066443-F19E39AD-B102-4E23-A7B5-8F5B64921519Q33217514-15438BB4-4747-4C1A-8DA8-BE8768B8F3C2Q33256633-4342F534-2780-480C-8751-60254F9A2AE1Q33396429-56AA5E37-F4B3-4DEC-98A5-892043B764F5Q33505445-833CF561-CEB9-4C53-8445-35F215E7630DQ33797188-063D6347-38E7-4EC6-B536-E67E1D827647Q34000174-B6D12BC6-B854-418E-AFFA-11FE467B79CCQ34117857-73D11A12-41FE-4621-9486-C30AEEE1A463Q34194649-6C5BFC2A-2DE8-4577-9022-20A4BD256F77Q34614260-1EBC96E4-7A19-430C-B37F-131667154A4AQ34629406-6531261D-0D97-4A42-9357-FACA334BD723Q34681152-79166F0F-FAF0-4503-A746-C9750897A975Q34714912-22C4F042-C60E-40DC-8568-C77E17408DD6Q35400677-37DE3EA3-9052-42DC-83DE-F00E59953B6CQ35560377-540B6072-25F8-4C96-BD1D-2E85926E4DC4Q35913511-781D0300-831E-410B-9F28-6B3AE91DE368Q36155940-358263FE-EB3D-4D0A-8A73-31D6FB15D557Q36226066-77F0389E-CB84-4943-BC6F-D1B51088BB92Q36294717-6FA9E738-2137-4AD6-8D24-EA3BC2824434Q36313906-E0157E39-BF86-44B1-B84F-82CB013DF6D2Q36432828-DE75EE30-8253-4B34-B567-75C470DBDAF5Q36523135-B298123C-0E14-4D56-8BFF-670020319171Q36530221-BF5E50BF-44E5-4BEF-A019-6FE995B3FD7FQ36673656-70DDC839-728D-40F9-B424-00E1CD3408BEQ36924602-46F78788-AA60-40E2-BC60-9A4FC8385328Q36958363-76A305D0-9017-496A-A272-20D3650C548DQ36964618-AFC7614D-430E-4A2E-81E0-64C2A281F3E6Q36976315-57015AE6-2393-4C22-A8A1-688049C69DF9Q36980383-0FC33642-2A2F-486C-8F75-99BE64DAE761Q37374866-04A9AE2C-287C-404D-8E74-FDE836304A0CQ37404847-7827810C-9B8B-4429-B98F-9D2266CF3AD5Q37424982-6377F34E-AD1B-4F05-9C92-8A6A2E9129B5
P2860
Comparative safety and efficacy against Bacillus anthracis of protective antigen and live vaccines in mice.
description
1988 nî lūn-bûn
@nan
1988 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1988 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1988年の論文
@ja
1988年論文
@yue
1988年論文
@zh-hant
1988年論文
@zh-hk
1988年論文
@zh-mo
1988年論文
@zh-tw
1988年论文
@wuu
name
Comparative safety and efficac ...... gen and live vaccines in mice.
@ast
Comparative safety and efficac ...... gen and live vaccines in mice.
@en
Comparative safety and efficac ...... gen and live vaccines in mice.
@nl
type
label
Comparative safety and efficac ...... gen and live vaccines in mice.
@ast
Comparative safety and efficac ...... gen and live vaccines in mice.
@en
Comparative safety and efficac ...... gen and live vaccines in mice.
@nl
prefLabel
Comparative safety and efficac ...... gen and live vaccines in mice.
@ast
Comparative safety and efficac ...... gen and live vaccines in mice.
@en
Comparative safety and efficac ...... gen and live vaccines in mice.
@nl
P1476
Comparative safety and efficac ...... gen and live vaccines in mice.
@en
P2093
Friedlander AM
P304
P356
10.1016/0882-4010(88)90015-0
P577
1988-08-01T00:00:00Z